International Cholangiocarcinoma Research Network (ICRN)

The ICRN is a global collaboration of research groups from renowned institutions who are working in concert to improve knowledge about cholangiocarcinoma etiology, prevention, early detection, treatment, and prognosis. The network is comprised of highly talented individuals from a spectrum of disciplines, perspectives, and research methods who share a passion to make significant scientific advances to improve outcomes for patients with cholangiocarcinoma.

The goal of ICRN is to accelerate the clinical translation of scientific discoveries to impact the lives of patients with cholangiocarcinoma.
  • Our core mission is to rapidly translate scientific discoveries into practice for cholangiocarcinoma patients through a collaborative, highly translational international research network
  • Improve the prognosis and quality of life for patients with cholangiocarcinoma, and ultimately cure this disease
  • Advance the pace of cholangiocarcinoma research
  • Provide a platform for investigators to work collaboratively on cholangiocarcinoma-related projects
  • Foster promising clinical and translational studies relevant to cholangiocarcinoma
  • Catalyze and expand patient access to clinical trials for promising new treatments
  • Enable scientists to rapidly share discoveries and accelerate the drug development landscape
  • Provide scientifically valid consensus opinions on the diagnosis and treatment of cholangiocarcinoma
Working Groups
Membership Eligibility
Membership Benefits

If your industry or biotech company or organization is interested in partnering with the ICRN for the purposes of cholangiocarcinoma research and potential collaboration, please fill out the ICRN Industry Request for Engagement form.

ICRN Members Map


If you'd like more information about the ICRN, please contact Reham Abdel-Wahab.

ICRN Executive Committee

Mitesh Borad, MD


Mayo Clinic, Arizona

Nilofer Saba Azad, M.D.

ICRN Co-Chair

Johns Hopkins


Laura Goff, MD

Biliary Cancer Alterations Predict Therapy Choice (BATCH)

Vanderbilt Ingram Cancer Center

Lipika Goyal

Lipika Goyal, MD

Biorepository and Genomic Research Workgroup Chair

Massachusetts General Hospital/Harvard University


Milind Javle, MD

Immediate Past Chair

UT MD Anderson Cancer Center

Eugene J. Koay, MD, PhD

Radio-diagnostic and Radiation Oncology Workgroup Chair

MD Anderson Cancer Center


Lewis Roberts, MB, ChB, PhD

Biorepository and Genomic Research Workgroup Chair

Mayo Clinic, Minnesota


Flavio Rocha, MD, FACS

Surgical & Transplantation
Workgroup Chair

Virginia Mason Medical Center


John Bridgewater, PhD

University College London Hospital, UK

Suebpong Tanasanvimon, MD

Bumrungrad International Hospital, Thailand

Advocacy Organization Hybrid Model for Advancing Research